Skip to main content
Atrás
ABBV logo

AbbVie Inc.

Calidad de datos: 100%
Sobreventa
ABBV
NYSE Healthcare Drug Manufacturers - General
$204.93
▼ $0.14 (-0.07%)
Cap. Mercado: 362.35B
Rango del Día
$203.24 $208.62
Rango de 52 Semanas
$164.39 $244.81
Volumen
7,340,882
Promedio 50D / 200D
$223.12 / $215.25
Cierre Anterior
$205.07

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E 85.7 0.4
P/B 2.9
ROE % 15367.3 3.8
Net Margin % 6.9 3.9
Rev Growth 5Y % 2.1 10.0
D/E 0.2

Precio Objetivo de Analistas

Hold
$256.15 +25.0%
Low: $223.00 High: $299.00
P/E Futuro
14.1
EPS Futuro
$14.57
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
67 B

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $20.05
$19.56 – $20.40
84 B 5
FY2029 $19.55
$19.07 – $19.89
82 B 10
FY2028 $17.87
$13.13 – $21.13
78 B 12

Puntos Clave

Revenue grew 2.14% annually over 5 years — modest growth
ROE of 15367.27% indicates high profitability
Generating 17.82B in free cash flow
P/E of 85.74 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 6.43%
Cash machine — converts 421.58% of earnings into free cash flow

Crecimiento

Revenue Growth (5Y)
2.14%
Revenue (1Y)8.57%
Earnings (1Y)-1.22%
FCF Growth (3Y)-10.14%

Calidad

Return on Equity
15367.27%
ROIC24.18%
Net Margin6.91%
Op. Margin34.69%

Seguridad

Debt / Equity
N/A
Current Ratio0.67
Interest Coverage8.08

Valoración

P/E Ratio
85.74
P/B RatioN/A
EV/EBITDA20.09
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8.57% Revenue Growth (3Y) 6.11%
Earnings Growth (1Y) -1.22% Earnings Growth (3Y) -6.78%
Revenue Growth (5Y) 2.14% Earnings Growth (5Y) -22.21%
Profitability
Revenue (TTM) 61.16B Net Income (TTM) 4.23B
ROE 15367.27% ROA 3.15%
Gross Margin 83.71% Operating Margin 34.69%
Net Margin 6.91% Free Cash Flow (TTM) 17.82B
ROIC 24.18% FCF Growth (3Y) -10.14%
Safety
Debt / Equity N/A Current Ratio 0.67
Interest Coverage 8.08 Dividend Yield 0.03%
Valuation
P/E Ratio 85.74 P/B Ratio N/A
P/S Ratio 5.92 PEG Ratio -116.18
EV/EBITDA 20.09 Dividend Yield 0.03%
Market Cap 362.35B Enterprise Value 426.19B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 61.16B 56.33B 54.32B 58.05B 56.20B
Net Income 4.23B 4.28B 4.86B 11.84B 11.54B
EPS (Diluted) 2.36 2.39 2.72 6.63 6.45
Gross Profit 51.20B 39.43B 33.90B 40.64B 38.75B
Operating Income 21.21B 9.14B 12.76B 18.12B 17.92B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 133.96B 135.16B 134.71B 138.81B 146.53B
Total Liabilities 137.19B 131.80B 124.31B 121.52B 131.09B
Shareholders' Equity -3.27B 3.33B 10.36B 17.25B 15.41B
Total Debt 69.07B 67.84B 60.12B 64.19B 77.58B
Cash & Equivalents 5.23B 5.52B 12.81B 9.20B 9.75B
Current Assets 29.06B 25.58B 33.00B 28.46B 27.93B
Current Liabilities 43.29B 38.75B 37.84B 29.54B 35.19B